key: cord-0863024-ycda91vq
authors: Stadtmauer, Edward A.; Sullivan, Keith M.; El Idrissi, Mohamed; Salaun, Bruno; Alonso Alonso, Aránzazu; Andreadis, Charalambos; Anttila, Veli-Jukka; Bloor, Adrian JC; Broady, Raewyn; Cellini, Claudia; Cuneo, Antonio; Dagnew, Alemnew F.; Di Paolo, Emmanuel; Eom, HyeonSeok; González-Rodríguez, Ana Pilar; Grigg, Andrew; Guenther, Andreas; Heineman, Thomas C.; Jarque, Isidro; Kwak, Jae-Yong; Lucchesi, Alessandro; Oostvogels, Lidia; Polo Zarzuela, Marta; Schuind, Anne E.; Shea, Thomas C.; Sinisalo, Ulla Marjatta; Vural, Filiz; Yáñez San Segundo, Lucrecia; Zachée, Pierre; Bastidas, Adriana
title: Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice
date: 2021-08-18
journal: Human vaccines & immunotherapeutics
DOI: 10.1080/21645515.2021.1953346
sha: e934309b299bd757de385692d51b2aff4203d41f
doc_id: 863024
cord_uid: ycda91vq

Immunocompromised individuals, particularly autologous hematopoietic stem cell transplant (auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth description of humoral and cell-mediated immune (CMI) responses by age (protocol-defined) or underlying disease (post-hoc) as well as efficacy by underlying disease (post-hoc) of the adjuvanted recombinant zoster vaccine (RZV) in a randomized observer-blind phase III trial (ZOE-HSCT, NCT01610414). 1846 adult auHSCT recipients were randomized to receive a first dose of either RZV or placebo 50–70 days post-auHSCT, followed by the second dose at 1–2 months (M) later. In cohorts of 114–1721 participants, at 1 M post-second vaccine dose: Anti-gE antibody geometric mean concentrations (GMCs) and median gE-specific CD4[2+] T-cell frequencies (CD4 T cells expressing ≥2 of four assessed activation markers) were similar between 18–49 and ≥50-year-olds. Despite lower anti-gE antibody GMCs in non-Hodgkin B-cell lymphoma (NHBCL) patients, CD4[2+] T-cell frequencies were similar between NHBCL and other underlying diseases. The proportion of polyfunctional CD4 T cells increased over time, accounting for 79.6% of gE-specific CD4 T cells at 24 M post-dose two. Vaccine efficacy against HZ ranged between 42.5% and 82.5% across underlying diseases and was statistically significant in NHBCL and multiple myeloma patients. In conclusion, two RZV doses administered early post-auHSCT induced robust, persistent, and polyfunctional gE-specific immune responses. Efficacy against HZ was also high in NHBCL patients despite the lower humoral response.

Herpes zoster (HZ) develops following the reactivation of latent varicella-zoster virus (VZV), particularly in individuals with reduced immune function, such as older adults, and in persons with acquired immunodeficiency or receiving immunosuppressive therapies. 1,2 It also commonly occurs in patients who have undergone allogeneic, syngeneic, or autologous hematopoietic stem cell transplant (HSCT), in whom T-cell immunity is diminished (incidence range: 16-30%). [3] [4] [5] [6] To prevent virus-associated infections, including HZ, antiviral prophylaxis is commonly administered to patients after HSCT. 7, 8 However, the efficacy of the prophylaxis is impacted by the adherence to medication and its duration and HZ risk increases once prophylaxis has been stopped. [8] [9] [10] Improved prevention strategies to provide sustained protection against HZ are therefore needed. 8 Vaccination can provide long-term protection, but live-attenuated vaccines are contraindicated in immunocompromised individuals due to the risk of disseminated disease. 11, 12 An adjuvanted recombinant zoster vaccine (RZV, Shingrix, GSK) demonstrated >90% vaccine efficacy against HZ in phase III clinical trials conducted in participants aged ≥50 and ≥70 years, 13, 14 and was first licensed in 2017 for use in adults aged ≥50 years. 15 Another study showed that immune responses to RZV persist at least ten years in adults vaccinated at age ≥60 years and modeling predicts that these will persist for up to 20 years. 16 As this is a non-live, recombinant subunit vaccine, there is no risk of it causing disseminated HZ in immunocompromised individuals, and RZV could represent an important strategy to prevent HZ in HSCT patients.

Due to diminished immunity following HSCT conditioning regimens, or due to the underlying malignancy, patients may be unable to mount an adequate protective immune response to vaccination given shortly after transplantation. 17 Nevertheless, autologous HSCT patients aged ≥18 years showed strong glycoprotein E (gE)-specific humoral and CMI responses to RZV in a phase I/IIa study and a phase III efficacy study (ZOE-HSCT) . 18, 19 In ZOE-HSCT, RZV administered 50-70 days posttransplant, demonstrated 68% efficacy (95% confidence interval [CI] 56-78) in preventing HZ and induced robust gE-specific humoral and CMI responses. 19 Here we further characterize gE-specific humoral and CMI responses by age and underlying diseases, and also present vaccine efficacy according to underlying diseases in the ZOE-HSCT study population.

This was a randomized, observer-blind, placebo-controlled, parallel-group phase III study, conducted in 167 centers in 28 countries (NCT01610414). The study protocol was reviewed and approved by relevant Institutional Review Boards or Independent Ethics Committees. The full study protocol is available as part of the primary publication. 19

Eligible adults aged ≥18 years had undergone autologous HSCT 50-70 days before the first dose of study vaccine. Detailed inclusion and exclusion criteria have been described previously. 19 Before study start, all participants provided written informed consent.

All eligible participants were randomized 1:1 to receive either RZV or placebo using a minimization procedure, which has been previously described. 19 At designated centers, participants were further randomly allocated to the humoral and CMI subcohorts until the sub-cohort targets were reached. The CMI subcohort included participants from Belgium, France, Japan, Spain, and the United States, who were enrolled at centers that had access within 24 hours from collection time to a peripheral blood mononuclear cell processing facility validated by GSK. The humoral immunity sub-cohort included participants from both the CMI sub-cohort and additional participants from designated centers in Australia, Canada, and Korea.

Vaccine/placebo doses were administered by unmasked study staff who did not participate in the study assessments. Further details on blinding undertaken for the assessment of efficacy have been presented previously. 19

Each 0.5 ml RZV dose contained recombinant VZV gE (50 μg) and the AS01 B adjuvant system (containing MPL, QS21, and liposome). 15 Placebo contained lyophilized sucrose reconstituted in 0.9% saline solution. The first dose was administered 50-70 days post-transplantation and the second dose one to two months (M) thereafter.

Vaccine efficacy against HZ (primary study outcome), HZ complications, and HZ-related hospitalizations, as well as safety and overall immunogenicity results, have been described previously. 19 Here we present humoral and CMI responses by age (18-49 years and ≥50 years), which were assessed in protocol-defined sub-group analyses. Vaccine efficacy against HZ and immunogeni 

Assessment of HZ cases and estimation of vaccine efficacy have been described in detail previously (Supplementary Text 1). 19 Blood samples (8 ml) were collected from all participants at prevaccination and 1 M post-dose two to contribute to the correlate of protection assessment (not reported here). These blood samples were used to evaluate humoral immunogenicity according to underlying diseases, which are described herein. Additional blood samples (8 ml) were taken from the humoral immunogenicity subcohort at 1 M post-dose one, and at 12 M and 24 M post-dose two. Participants in the CMI sub-cohort provided additional 30 ml blood samples at all five predefined study visits.

Anti-glycoprotein E (gE) antibody concentrations were measured using a previously described assay. 20 The frequency of gE-specific CD4 T cells expressing at least two of the following activation markers (CD4[2+] T cells) per 10 6 CD4 T cells was calculated: interferon-γ (IFN-γ), interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α), and CD40 ligand (CD40L). For the analysis of gE-specific T-cell polyfunctionality, the frequency of CD4 T cells expressing one or any combination of two, three, or four of the four activation markers assessed was calculated. Additional details have been disclosed previously, 20 and are as described in Supplementary Text 2.

All endpoints presented here are descriptive. Therefore, no formal sample size calculations were performed for these analyses.

Post-hoc vaccine efficacy evaluation and analyses of humoral immunity according to underlying diseases were performed on the modified total vaccinated cohort, which included all participants who received both doses and did not develop HZ before 1M post-dose two. Humoral immune responses according to underlying diseases were evaluated in the modified total vaccinated cohort (from samples collected for the correlate of protection assessment, which is not reported here) rather than in the according-to-protocol immunogenicity sub-cohort to provide a greater sample size in each subgroup.

Humoral immune responses per age and CMI responses per age and underlying diseases were assessed in the according-toprotocol immunogenicity cohorts, which included all eligible participants from the humoral and CMI sub-cohorts, respectively, who received both doses, complied with the protocol and had available immunogenicity endpoint measurements.

Anti-gE antibody geometric mean concentrations (GMCs) and their 95% CIs were determined. The vaccine response in terms of anti-gE antibody concentration (i.e., humoral vaccine response) was defined as a ≥4-fold increase in the anti-gE antibody concentration compared either with the prevaccination concentration (initially seropositive participants) or with the anti-gE antibody cutoff value for seropositivity (97 milli-International Units per milliliter [mIU/mL]) (initially seronegative participants).

The vaccine response in terms of CD4[2+] T cell frequency (i.e., CMI vaccine response) was defined as a ≥2-fold increase in the frequency of CD4[2+] T cells, as compared to prevaccination frequency (for participants with pre-vaccination CD4[2+] T-cell frequency ≥320 per 10 6 CD4 T cells counted) or the cutoff (for participants with pre-vaccination frequencies below the cutoff).

Exact 95%CIs were computed at each time point for the humoral and CMI vaccine response rate using the Clopper Pearson exact method. The 95%CI for the GMCs was computed by anti-log transformation of the 95%CI for the mean of log-transformed concentrations.

The statistical analyses were performed using SAS Drug Development.

Characteristics of the overall study population, as well as reasons for withdrawals from the modified total vaccinated cohort have been previously published. 19 Of the 1846 participants (RZV: 922, placebo: 924) vaccinated between 13 July 2012 and 31 July 2015, 1721 (RZV: 870, placebo: 851) were included in the modified total vaccinated cohort and 158 (RZV: 82, placebo: 76) were included in according-to-protocol cohort for humoral immunogenicity at 1M post-dose two, of whom 114 (RZV: 59, placebo: 55) were also included in the accordingto-protocol cohort for CMI at 1M post-dose two ( Figure 1 ).

The demographic characteristics were balanced between the RZV and placebo groups in all cohorts evaluated (Table 1 ) and comparable to the TVC. 19 Most participants were white, male, and aged ≥50 years, and MM and NHBCL were the predominant underlying diseases.

Before vaccination, ≥82.4% of participants were seropositive for anti-gE antibody across age cohorts and study groups. In RZV group participants aged 18-49 and ≥50 years, respectively, the humoral vaccine response rate was 57.7% (95%CI 36.9-76.6) and 71.4% (57.8-82.7) at 1 M post-dose two and 23.1% (5.0-53.8) and 56.0% (34.9-75.6) at 24 M post-dose two. In placebo group participants, the humoral vaccine response rate was ≤22.2% across age cohorts and time points. In RZV group participants aged 18-49 and ≥50 years, respectively, anti-gE antibody GMCs were 1011.0 (95%CI 629.7-1623. Table 1 ).

In RZV group participants aged 18-49 and ≥50 years, respectively, the CMI vaccine response rate was 100% (95%CI 76.8-100) and 89.3% (71.8-97.7) at 1 M post-dose two, and 100% (59.0-100) and 58.8% (32.9-81.6) at 24 M post-dose two. In placebo group participants, the CMI vaccine response rate was ≤20.0% across age cohorts and time points. In RZV group Table 2) .

In the RZV group, the humoral vaccine response rate at 1 M post-dose two was lower among NHBCL patients (14.2%, 95% CI 9.9-19.4) compared to patients with any of the other underlying diseases (≥69.6%). In the placebo group, the humoral vaccine response rate was ≤3.0% across underlying diseases at 1 M post-dose two. In the RZV group, anti-gE antibody GMCs increased substantially (i.e., >9-fold) at 1 M post-dose two compared to pre-vaccination irrespective of the underlying disease with the exception of NHBCL (<2-fold increase). No increases were observed in placebo recipients (Figure 3(a,b) , Supplementary Table 3) .

Due to the relatively limited size of the CMI sub-cohort, at each time point, few participants with underlying diseases other than MM or NHBCL had available data. In the RZV group, the (Figure 3(c,d) , Supplementary Table 2) .

CD40L was the most commonly expressed marker at all time points, followed by IL-2. IFN-γ and TNF-α were usually expressed in combination with CD40L and/or IL-2. The frequencies of CD4 T cells expressing individual and combinations of activation markers were highest at 1 M post-dose two (peak of the measured response) and decreased thereafter (Figure 4) . Compared to pre-vaccination, the proportion of CD4 T cells expressing only one activation marker decreased from 65.7% to 27.0% and 10.6% 1 M after RZV doses one and two, respectively, while the proportion of polyfunctional CD4 T cells (expressing three or four activation markers) increased from 19.1% to 55.1% and 69.0%, respectively. The proportion of polyfunctional CD4 T cells continued to increase up to 79.6% at 24 M post-dose two ( Figure 5 ).

Vaccine efficacy against HZ was 72.4% (95% CI 54.8-83.7, p = .0001) in MM and 60.5% (31.0-78.2, p = .0006) in NHBCL patients. Vaccine efficacy was also observed for all other underlying diseases (42.5%-100%), albeit not statistically significant ( Table 2 ).

Robust humoral and CMI responses were elicited in participants aged 18-49 and ≥50 years, with no major differences between the two age cohorts. While humoral immune responses declined to close to baseline levels in 18-49-year-olds through 24 M postvaccination, CMI remained high in both age cohorts. Efficacy of RZV was similar in these two age cohorts, 19 consistent with the fact that CMI responses are believed to be the main mechanistic driver for protection against HZ. 21 The frequencies of gE-specific CD4[2 +] T cells after vaccination in autologous HSCT patients aged ≥50 years were higher than those previously reported in immunocompetent adults aged ≥50 years, using the same assay. 20 This may be explained by the proliferation triggered post-vaccination in a not yet fully reconstituted immunological space, and thus without the classical homeostatic control. Additionally, as the data are Figure 5 . Relative mean frequencies of CD4 T cells expressing 1, 2, 3, or 4 activation markers (adapted † according-to-protocol cohort for cell-mediated immunity -RZV group only). M = month; RZV = adjuvanted recombinant zoster vaccine. Data labels represent percentages of mean frequencies of CD4 T cells expressing any combination of 1, 2, 3, or 4 activation markers from: CD40 ligand; interferon-γ, interleukin-2, tumor necrosis factor-α † Adapted denotes that for each time point presented, the corresponding according-to-protocol cohort was used. Censored at the first occurrence of a confirmed herpes zoster episode and at the occurrence of treatment for relapse. ‡ p-value = Two-sided exact p-value conditional to number of cases.

expressed as frequencies per 10 6 CD4 T cells, the low number of total CD4 T cells may lead to a higher proportion of gE-specific CD4[2+] T cells following vaccination early post-transplant.

Underlying diseases appeared to have little impact on the humoral immune responses, except for NHBCL, as these patients commonly receive immunotherapeutic agents specifically targeting B cells, such as anti-CD 20 antibodies, humoral responses were expected to be low. 22 This is consistent with the blunted postvaccination anti-gE immune response observed in a phase I/II trial of RZV in autologous HSCT recipients, which was attributed to B-cell depletion during pre-HSCT conditioning lymphoma treatment. 18 In contrast, underlying diseases (including NHBCL) did not appear to impact the CMI responses, which is in line with previous observations in autologous HSCT recipients. 18 In NHBCL patients, RZV was >60% efficacious against HZ, supportive of the belief that CMI responses are the main mechanistic driver for protection against HZ. 21 Polyfunctional CD4 T-cell responses have been shown to correlate with efficacy of vaccination against human immunodeficiency virus, tuberculosis, malaria, or melanoma. [23] [24] [25] [26] Cunningham et al postulated the importance of gE-specific polyfunctional CD4 T-cell responses in driving the high efficacy of RZV against HZ in adults aged ≥50 years. 20 These findings were later confirmed in the control arm of a trial evaluating immunogenicity of RZV in previous liveattenuated zoster vaccine (ZVL, Zostavax, Merck Sharp & Dohme Corp.) recipients. 27 In a similar evaluation, polyfunctionality was assessed in this study selecting the following four T-cell markers: IL-2, CD40L, which are the dominant activation markers shortly post-vaccination, 20 and IFN-γ and TNFα, which correlate best with vaccine-induced protection. 28, 29 The proportion of polyfunctional CD4 T cells increased from 1 M to 24 M post-second vaccine dose, an increase observed previously in adults aged ≥50 years. 20 Of interest in the specific context of HSCT, the high proportion (>50%) of polyfunctional gE-specific CD4 T cells 1 M post-first vaccine dose may suggest the presence of gE-specific memory T cells in the transplanted grafts, which would be readily recalled by the first vaccine dose and further amplified by the second dose. It is unclear whether naïve or effector memory T cells predominate in the expansion phase after vaccination with ZVL, although it has been proposed that broadening of VZVspecific T-cell repertoire occurs through preferential expansion of infrequent T-cell clones, including recruitment of new specificities from the naïve repertoire. 30 Further investigations would be required to evaluate whether this also applies to RZV.

Vaccination increased the frequency of IL-2-producing CD4 T cells. It was recently proposed that IL-2 expression at the peak of the response is required for CD4 T-cell response persistence, and this may be a key differentiator between RZV and ZVL, which may explain the observed differences in both immune responses and efficacy. 28 ZVL induces an effector response profile dominated by IFN-ɣ, which wanes rapidly over time, while the memory T-cell profile induced by RZV, linked to IL-2 production, may explain the long-term persistence of both cellular responses and vaccineinduced protection. As in the overall study population, 19 efficacy against HZ was observed for each underlying disease, although due to the small sample size and few incident HZ episodes, it was not statistically significant for some of these.

For establishing the optimal timing of vaccination in HSCT patients, several factors need to be considered, such as the long-term effect of conditioning regimens, post-transplant immune reconstitution and immunosuppressive regimens, Figure 6 . Plain language summary. and post-transplant antiviral prophylaxis. At odds with the previous observation that HSCT patients may be unable to mount a protective immune response to vaccination when given shortly after transplantation, 17 this study demonstrated both high vaccine efficacy and strong immune responses after the two-dose RZV course initiated 50-70 days post-autologous HSCT. 19 This is especially important to inform health care providers on timing of vaccination when protection against vaccine-preventable diseases is imperative early posttransplant such as the protection against Coronavirus Disease 2019 (COVID- 19) , for which treatment options and other prophylactic interventions are currently very limited. In addition, the efficacy of the evaluated RZV regimen against HZ was similar between autologous HSCT recipients who received no antiviral prophylaxis and those who received antiviral prophylaxis for up to 60 days after 1 M post-dose two, 19 confirming the added benefit of vaccination early post-transplant. It also suggests that antiviral prophylaxis for the purpose of HZ prevention may be stopped at 6 M post-autologous HSCT, when the vaccine-elicited protection against HZ has already been achieved. While smaller studies showed that RZV (administered at a median 8-9 months post-transplant) was also welltolerated in allogenic HSCT recipients, it was less immunogenic than in autologous HSCT recipients. 31, 32 However, administration of RZV before full immune reconstitution as well as its efficacy are yet to be evaluated in allogenic HSCT recipients.

Potential limitations of these descriptive analyses are mostly related to the small sample size and low HZ incidence in some sub-groups along with the post-hoc nature of most presented analyses, which also impact the robustness of efficacy data by underlying diseases. Details of pre-transplant conditioning treatment such as rituximab were only recorded for thirty days before transplant, and the information on the impact of specific long-lasting treatments on immune responses is incomplete. Nevertheless, the vaccine was administered 50-70 days after the autologous HSCT, when the immune system suppression was still near its maximum, 33 and these descriptive analyses provide important insight for understanding the effect of the vaccine in this immunocompromised population. Although the follow-up period for efficacy was relatively short, it covered the first year post-transplant, prior to complete immunological recovery in some instances, when the risk of HZ is the highest. 33 A plain language summary contextualizing the results and potential clinical research relevance and impact is presented in Figure 6 .

In conclusion, two RZV doses, administered 50-70 days post-transplant, induced strong and persistent humoral and CMI responses irrespective of age, and robust CMI responses irrespective of underlying diseases in adults who had undergone autologous HSCT. Glycoprotein E-specific CD4 T-cell responses were polyfunctional, and the proportion of polyfunctional CD4 T cells increased through year two postvaccination. Post-hoc analysis of efficacy against HZ for each underlying disease was consistent with efficacy in the overall population studied, 19 and vaccine efficacy was also high in NHBCL patients despite the weaker humoral immune responses. RZV, currently licensed in several countries for all adults aged ≥50 years and in Europe for adults aged ≥18 years at increased risk of HZ, has the potential to represent an additional prophylactic intervention in the care of patients after autologous HSCT, at high risk for HZ.

Charalambos Andreadis

Lidia Oostvogels

Filiz Vural

Adriana Bastidas

References 1. Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence

Quantification of risk factors for herpes zoster: population based case-control study

Herpes zoster in autologous hematopoietic cell transplant recipients in the era of acyclovir or valacyclovir prophylaxis and novel treatment and maintenance therapies

A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitor cell transplantation

Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation

Cell-mediated immunity to varicella-zoster virus after allogeneic marrow transplant

Lowdose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation

Duration of antiviral prophylaxis and risk of herpes zoster among patients receiving autologous hematopoietic stem cell transplants: a retrospective, observational study

Antiviral prophylaxis for preventing herpes zoster in hematopoietic stem cell transplant recipients: A systematic review and metaanalysis

Varicella zoster virus reactivation in adult survivors of hematopoietic cell transplantation: how do we best protect our patients?

Herpes zoster vaccine live: a 10 year review of post-marketing safety experience

Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection. Vaccine

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults

Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older

Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention

Immunogenicity of the adjuvanted recombinant zoster vaccine: persistence and anamnestic response to additional doses administered 10 years after primary vaccination

Vaccination of hematopoietic cell transplant recipients

A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients

Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial

Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older

VZV T cell-mediated immunity

Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

Role of occult and post-acute phase replication in protective immunity induced with a novel live attenuated SIV vaccine

Increased TNFalpha/IFN-gamma/IL-2 and Decreased TNF-alpha/IFN-gamma production by central memory T cells are associated with protective responses against bovine tuberculosis following BCG vaccination

Sterile protection against human malaria by chemoattenuated PfSPZ vaccine

Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients

The adjuvanted recombinant zoster vaccine in adults aged ≥65 years previously vaccinated with a liveattenuated herpes zoster vaccine

Th1 memory differentiates recombinant from live herpes zoster vaccines

Features of effective T cell-inducing vaccines against chronic viral infections

Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination

Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study

Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation

Immune reconstitution after hematopoietic cell transplantation

The authors would like to thank Agnes Mwakingwe-Omari for her support in the development of this manuscript, the study participants, investigators and study teams involved in this trial, as well as the GSK Teams: Laboratory teams who undertook the immunological assessments, Clinical Research & Development, Clinical Operations, Statisticians and Stat Analysts, Medical Data Reviewers, Safety Case Management, and Publications.Medical writing services were provided by Alpár Pöllnitz (Modis; Cluj-Napoca, Romania; on behalf of GSK). Editorial assistance and publication coordination were provided by Sander Hulsmans (Modis; Wavre, Belgium; on behalf of GSK).

Anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.

The authors declare the following financial relationships: During the conduct of the study, CA, and EAS report grants from the GSK group of companies (GSK); VJA reports Phase III study compensation from GSK to the research institute; and KMS reports a grant and personal fees from GSK and a grant from NIAID and NIH awarded to Duke University. Outside the submitted work, VJA reports study grants from Pfizer, and personal fees from Astellas, MSD, Pfizer, Roche, and Unimedic; AGr has served on the Advisory Boards of Bristol Myers Squibb, Gilead, MSD, Novartis, Roche, and Takeda; AGu reports personal fees from Celgene, Takeda, Janssen-Cilag, Novartis, Teva, and Jazz; and KMS reports personal fees from Kiadis Pharmaceutical, and Roche Genentech. During the design, initiation, conduct of the study and/or interpretation of the data, AB, AFD, EDP, MEI, TCH, LO, BS, and AES were employees of GSK. They also own shares in the GSK group of companies. AB, AFD, and LO are currently 

This work was sponsored by GlaxoSmithKline Biologicals SA in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA also took responsibility for all costs associated with the development and publishing of the present manuscript.

Shingrix is a trademark of the GSK group of companies. Zostavax is a trademark of Merck Sharp & Dohme Corp.